729 results on '"Bot, Adrian"'
Search Results
2. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
3. Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling
4. Abstract 13851: CAR-T Cells: A Potential Novel Strategy for Mitigating Fibrosis in Duchenne Muscular Dystrophy
5. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
6. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
7. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
8. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
9. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
10. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
11. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
12. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
13. Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
14. Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
15. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
16. Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma
17. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
18. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
19. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
20. 1202 In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology
21. 312 IL7 increases targeted lipid nanoparticle-mediated mRNA protein expression in T cellsin vitroandin situby enhancing T cell translation
22. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
23. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
24. IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation.
25. POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
26. ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
27. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
28. A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
29. New section in journal of translational medicine: patient-targeted molecular therapies
30. Data from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
31. Supplementary Table S1 from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
32. Supplementary Figures from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
33. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma
34. Supplementary Data from Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial
35. Supplementary Data from Lymph Node–Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus–Transformed Tumors
36. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
37. Contributors
38. Cancer Vaccines
39. 687 Proteomic profiling in blood identifies novel pretreatment and mechanistic markers related to inflammatory adverse events in relapsed/refractory large B-cell lymphoma after axicabtagene ciloleucel
40. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
41. Intralymphatic Vaccination
42. Immune Responses Elicited by Genetic Immunization with Bacterial, Fungal, or Parasitic Antigens
43. Genetic Immunization against Tumors
44. Genetic Vaccination of Neonates
45. Autoimmunity, Allergy, and Genetic Vaccines
46. Protective Immune Responses Elicited by Genetic Immunization against Viruses
47. Genetic Vaccination : Routes and Formulations
48. Cellular Mechanisms Involved in the Immune Response Elicited by Genetic Immunization
49. Intrinsic Adjuvant Properties of Plasmid DNA
50. Approaches for Development of New Vaccines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.